Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan Keqian Biology CoSHSE:688526 -0.32%81 FCF Margin % is 48.99% as of Jun. 2026, which is 46% above its 10-year median of 33.59. GuruFocus rates SHSE:688526 with a GF Score™ of 81/100 and a GF Value™ of ¥13.70 (Fairly Valued). The stock has 6 warning signs investors should review. Among 974 Biotechnology companies, Wuhan Keqian Biology Co ranks better than 95.38% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688526 vs VRTX, REGN, MRNA: FCF Margin % Comparison
For the Biotechnology subindustry, Wuhan Keqian Biology Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Keqian Biology Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Wuhan Keqian Biology Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Keqian Biology Co (SHSE:688526) has a FCF Margin % of 48.99% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Wuhan Keqian Biology Co and its competitors. This is 46% above median its historical median of 33.59. Over the past decade, Wuhan Keqian Biology Co's FCF Margin % has ranged from 3.38 to 49.07. According to the industry distribution chart, Wuhan Keqian Biology Co ranks #45 out of 974 companies in the Biotechnology industry, placing it in the top 4.6%.
Is Wuhan Keqian Biology Co's FCF Margin % too high?
Wuhan Keqian Biology Co's current FCF Margin % of 48.99% is 46% above median its 10-year median of 33.59. Over the past 10 years, this metric has ranged from a low of 3.38 to a high of 49.07. Based on the distribution chart, Wuhan Keqian Biology Co ranks #45 out of 974 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Wuhan Keqian Biology Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wuhan Keqian Biology Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan Keqian Biology Co ranks #45 out of 974 companies for FCF Margin %. This places Wuhan Keqian Biology Co in the top 5% of its industry — outperforming the majority of peers. Historically, Wuhan Keqian Biology Co's own FCF Margin % has ranged from 3.38 to 49.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Wuhan Keqian Biology Co and its competitors. Wuhan Keqian Biology Co's current FCF Margin % is 48.99%, which is 46% above median its own 10-year median of 33.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Keqian Biology Co stock overvalued right now?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co (SHSE:688526) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.70, compared to a current price of ¥12.45 — trading 9.1% below its estimated fair value. The current FCF Margin % is 48.99%, which is 46% above median its 10-year median of 33.59. Wuhan Keqian Biology Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Wuhan Keqian Biology Co (SHSE:688526), the current FCF Margin % is 48.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuhan Keqian Biology Co (SHSE:688526) Overvalued in 2026?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co stock appears to be undervalued.
The current stock price of ¥12.45 is trading 9.1% below its estimated GF Value™ of ¥13.70.
GuruFocus considers Wuhan Keqian Biology Co to be Fairly Valued.
Key valuation signals for SHSE:688526:
FCF Margin %: 48.99% (46% above median its 10-year median of 33.59)
GF Value™: ¥13.70 vs. price of ¥12.45 (9.1% below fair value)
No single metric tells the full story. See the SHSE:688526 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuhan Keqian Biology Co Ltd is a Chinese veterinary biotechnology company engaged in the research, development, production, and sale of veterinary biological products, along with animal disease prevention and control technical services. Its core offerings are vaccines and related biologics for livestock and poultry, principally swine and avian vaccines, used by large-scale farms, breeding enterprises, and veterinary clinics across China. The company also provides diagnostic and technical support services tied to disease prevention programs. Revenue is generated mainly through the sale of veterinary vaccines and biological products, supplemented by technical service fees. Its operations and customer base are concentrated in the domestic Chinese market, where demand is driven by the scale and health management needs of the country's intensive animal husbandry sector. The company is listed on the Shanghai Stock Exchange's STAR Market.
81GF Score
Get the complete analysis for SHSE:688526
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688526 has been successfully added to your 
